As of 2026-07-17 · Last updated: 2026-07-18 · Source: SEC EDGAR (XBRL companyfacts, CIK 0000001800), stockanalysis (price, statistics, financial statements, ratios, consensus), Company IR · Prices & financials updated periodically (not real-time) · Information tool (not investment advice)
Debt is smaller than equity and it can meet short-term obligations.
Metrics · D/E ~65% · Current Ratio 1.39
💲Is the price expensive now?
On the expensive side
Even accounting for growth expectations, the price is set high.
Metrics · P/E 32.6 · P/B 3.4
💡Four segments diversify risk. An 18.6% operating margin and ~10% ROE, a 54-year Dividend King, with debt a moderate 0.65x equity.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: stockanalysis (margins, debt, liquidity, P/B, ROE are TTM), as of 2026-07-17
Business Summary · Key Value Metrics
A diversified healthcare company spanning four segments: Diagnostics, Medical Devices (including the FreeStyle Libre continuous glucose monitor), Nutrition (Similac, Ensure), and Established Pharmaceuticals. TTM revenue $46.6B with an 18.6% operating margin. In 2013 it spun off its research-based pharma arm as AbbVie.
Current Price
$100.68
+1.87%+$1.85· Close 2026-07-17
Analyst Consensus Target (external reference)
$118.33
Avg. of 27 external analysts · stockanalysis (27-analyst consensus, Buy)
P/E (TTM)
32.6x
TTM
ROE
10.3%
TTM
Operating Margin
18.6%
TTM
Net Margin
11.7%
TTM
Dividend Yield
2.50%
54 years of raises
Market Cap
$175.4B
As of 2026-07-17
Economic Moat · Key Business Segments
Abbott is diversified across four segments — Diagnostics, Medical Devices, Nutrition, and Established Pharmaceuticals — so weakness in one is cushioned by the others. Its FreeStyle Libre continuous glucose monitor (CGM) holds a leading position in the global diabetes-management market, and Abbott is a Dividend King that has raised its payout for 54 consecutive years (source: company IR · stockanalysis).
Business diversification
Four segments — diagnostics, devices, nutrition, and established pharma — so weakness in one is offset by the others.
FreeStyle Libre leadership
A market-leading continuous glucose monitor (CGM) and a key beneficiary of fast-growing diabetes management.
Emerging-market distribution
Established Pharmaceuticals and Nutrition reach 160+ emerging-market countries through channels rivals struggle to replicate.
Dividend stability
54 consecutive years of dividend increases earn Dividend King status, with a payout ratio near 69%.
10-Year Financial Trends
Revenue grew at a 9-year CAGR of +8.7% (2016 $20.9B → 2025 $44.3B), boosted by the 2017 acquisitions of St. Jude Medical and Alere. Operating income (+10.9%), net income (+18.6%), and EPS (+16.5%) rose alongside it. Note, though, that 2024 net income of $13.4B (diluted EPS $7.64) reflected a roughly $6.4B one-time net tax credit; results normalized in 2025 to $6.5B net income (diluted EPS $3.72). In Q2 2026, revenue rose 13.0% YoY to $12.6B (GAAP operating income $1.69B, -17.5%), and 2026 adjusted EPS guidance was raised to $5.45–5.60 (source: SEC EDGAR 10-K · company earnings).
10-Year Growth
Revenue$44.3B · CAGR +8.7%
Operating Income$8.1B · CAGR +10.9%
EPS$3.72 · CAGR +16.5%
10-Year Valuation
P/E (year-end)33.7x · avg 29.2x
ROE13.0% · avg 19.7%
Operating Margin18.2% · avg 15.3%
📊 Annual Data Table (ABT) — expand/collapse
Year
Revenue (B$)
Op. Income (B$)
EPS ($)
P/E (x)
ROE (%)
Op. Margin (%)
2016
20.9
3.2
0.94
—
—
15.3
2017
27.4
1.7
0.27
—
—
6.3
2018
30.6
3.7
1.33
—
—
11.9
2019
31.9
4.5
2.06
—
—
14.2
2020
34.6
5.4
2.5
—
—
15.5
2021
43.1
8.4
3.94
35.72
20.49
19.6
2022
43.7
8.4
3.91
28.08
19.01
19.2
2023
40.1
6.5
3.26
33.76
15.11
16.2
2024
42
6.8
7.64
14.81
30.91
16.3
2025
44.3
8.1
3.72
33.68
12.96
18.2
— = no data for that year/metric (P/E omitted before EPS turned positive)
9-Year CAGR: Revenue +8.7% · Operating Income +10.9% · Net Income +18.6% · EPS +16.5%
Sources: SEC EDGAR XBRL (companyfacts, CIK 0000001800) · stockanalysis · company earnings releases (8-K). Fiscal-year (December) GAAP basis; EPS is diluted. P/E and ROE cover the last 5 years (stockanalysis) due to data limits, while revenue, operating income, EPS, and operating margin span 10 years. The 2018 revenue-recognition change (ASC 606) and the St. Jude Medical and Alere acquisitions enlarged the 2017→2018 top line. In 2024, GAAP net income, EPS, and ROE surged on a roughly $6.4B one-time tax benefit before normalizing in 2025.
Mega-Cap Value Metric Comparison
Johnson & Johnson has the highest operating margin (26.9%), while Abbott (18.6%) and Medtronic (20.0%) are similar. Abbott trades at the highest P/E (32.6), and Medtronic offers the highest dividend yield (3.39%) (source: stockanalysis).
Infant-formula (NEC) litigation— Numerous lawsuits allege that a preterm-infant formula (Similac Special Care 24) caused necrotizing enterocolitis (NEC). Large damage risks continue, including a 2024 Missouri jury verdict of $495M (upheld on appeal) and a $70M Illinois verdict in April 2026.Source: Court rulings · media reports
●
GAAP earnings volatility— 2024 GAAP net income and EPS spiked on a roughly $6.4B one-time tax benefit before normalizing in 2025. Reading annual GAAP figures alone can misrepresent the true operating trend.Source: SEC EDGAR
●
Intensifying device competition— FreeStyle Libre faces intensifying competition in the continuous glucose monitor (CGM) market from Dexcom and others.Source: Company 10-K Risk Factors
●
Currency risk— With a high share of overseas sales, a stronger dollar can weigh on revenue and profit through translation losses.Source: Company 10-K Risk Factors
✦ ValueCrab Dashboard PreviewABT $100.68 +1.87% · as of 2026-07-17
Q. What are Abbott's (ABT) key value-investing metrics?P/E (TTM) 32.6, ROE 10.3%, operating margin 18.6%, net margin 11.7%, dividend yield 2.50%, and a 9-year revenue CAGR of +8.7% (source: stockanalysis, as of 2026-07-17).
Q. How is Abbott as a dividend stock?As a Dividend King that has raised its payout for 54 consecutive years, its dividend stability is very high. The current yield is about 2.50% with a payout ratio near 69%. (This is informational and not a buy or sell recommendation.)
Q. Why did 2024 net income suddenly spike?2024 GAAP net income of $13.4B (diluted EPS $7.64) reflected a roughly $6.4B one-time tax benefit. In 2025, net income returned to a normal $6.5B (diluted EPS $3.72) (source: SEC EDGAR 10-K).
Q. Who are the main competitors?Among healthcare large caps, Johnson & Johnson (JNJ) is a key peer, and in medical devices, Medtronic (MDT). Abbott stands out for its diversification across four businesses: diagnostics, devices, nutrition, and established pharmaceuticals.